Bevyxxa
Author: Cameron Findlater
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Bevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness. It is currently the only anticoagulant approved for extended use in both hospital and out-patient settings. The medication is an oral, once-daily factor Xa inhibitor. By directly inhibiting factor Xa, Bevyxxa reduces thrombin generation, thrombus formation, and thrombin-induced platelet aggregation, thus preventing blood clots.
TABLE OF CONTENTS
4 Product Profiles
4 Bevyxxa : Venous thromboembolism (VTE)
LIST OF FIGURES
7 Figure 1: Bevyxxa for venous thromboembolism – SWOT analysis
8 Figure 2: Datamonitor Healthcare’s drug assessment summary of Bevyxxa for venous thromboembolism
9 Figure 3: Datamonitor Healthcare’s drug assessment summary of Bevyxxa for venous thromboembolism
LIST OF TABLES
5 Table 1: Bevyxxa drug profile
6 Table 2: Bevyxxa pivotal trial data in venous thromboembolism
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Interventional Cardiology Vascular Stents 
Sign up to the